Neuroprotection Against Focal Ischemic Brain Injury by Inhibition of C-Jun N-terminal Kinase and Attenuation of the Mitochondrial Apoptosis-signaling Pathway
Overview
Endocrinology
Neurology
Authors
Affiliations
c-Jun N-terminal kinase (JNK) is an important stress-responsive kinase that is activated by various forms of brain insults. In this study, we have examined the role of JNK activation in neuronal cell death in a murine model of focal ischemia and reperfusion; furthermore, we investigated the mechanism of JNK in apoptosis signaling, focusing on the mitochondrial-signaling pathway. We show here that JNK activity was induced in the brain 0.5 to 24 h after ischemia. Systemic administration of SP600125, a small molecule JNK-specific inhibitor, diminished JNK activity after ischemia and dose-dependently reduced infarct volume. c-Jun N-terminal kinase inhibition also attenuated ischemia-induced expression of Bim, Hrk/DP5, and Fas, but not the expression of Bcl-2 or FasL. In strong support of a role for JNK in promoting the mitochondrial apoptosis-signaling pathway, JNK inhibition prevented ischemia-induced mitochondrial translocation of Bax and Bim, release of cytochrome c and Smac, and activation of caspase-9 and caspase-3. The potential mechanism by which JNK promoted Bax translocation after ischemia was further studied using coimmunoprecipitation, and the results revealed that JNK activation caused serine phosphorylation of 14-3-3, a cytoplasmic sequestration protein of Bax, leading to Bax disassociation from 14-3-3 and subsequent translocation to mitochondria. These results confirm the role of JNK as a critical cell death mediator in ischemic brain injury, and suggest that one of the mechanisms by which JNK triggers the mitochondrial apoptosis-signaling pathway is via promoting Bax and Bim translocation.
Lee A, Bi S, Ridgeway E, Al-Hussaini I, Deshpande S, Krueger A Int J Mol Sci. 2025; 26(3).
PMID: 39940644 PMC: 11817447. DOI: 10.3390/ijms26030872.
Yu L, Jin W, Deng D, Wang Y, Chen Q, Zhang Y CNS Neurosci Ther. 2025; 31(1):e70209.
PMID: 39764606 PMC: 11705586. DOI: 10.1111/cns.70209.
Gong Z, Guo J, Liu B, Guo Y, Cheng C, Jiang Y Front Immunol. 2024; 14:1287857.
PMID: 38274789 PMC: 10808662. DOI: 10.3389/fimmu.2023.1287857.
Neuroprotective Effects of Tryptanthrin-6-Oxime in a Rat Model of Transient Focal Cerebral Ischemia.
Plotnikov M, Chernysheva G, Smolyakova V, Aliev O, Anishchenko A, Ulyakhina O Pharmaceuticals (Basel). 2023; 16(8).
PMID: 37630972 PMC: 10457995. DOI: 10.3390/ph16081057.
Rajan R, Kumar R, Ramanathan M Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(1):479-496.
PMID: 37470802 DOI: 10.1007/s00210-023-02616-0.